Determinant factors of sarcopenia in individuals with Parkinson's disease.

OBJECTIVE: Evaluate the occurrence of sarcopenia and determinant factors in individuals with Parkinson's disease (PD) in a city in northeastern Brazil. METHODS: Case series with 77 men and women (adults and older adults) with PD. The risk of sarcopenia was determined using the SARC-F and SARC-CalF screening tools. The diagnosis of sarcopenia was based on the new consensus published by the European Working Group on Sarcopenia in Older People (EWGSOP2). Sarcopenic obesity was diagnosed based on the criteria proposed by Stenholm. Disease stage and severity were determined using the Hoehn and Yahr scale and the Unified Parkinson Disease Rating Scale, respectively. RESULTS: The prevalence of sarcopenia was 19.5% and was associated with age, poor performance on activities of daily living and poor nutritional status. No significant association was found between the SARC-F score and the diagnosis of sarcopenia. The main factors that determined the variation in the parameters for the diagnosis of sarcopenia in the present sample were age, disease severity, body weight, and SARCF score. CONCLUSION: Despite the low prevalence in the present study, sarcopenia progresses with the worsening of the nutritional status and functional capacity of individuals with PD. Further studies are needed on the factors involved in the genesis of sarcopenia. The SARC-F questionnaire is related to parameters for the diagnosis and severity of sarcopenia as well as the severity of PD.

Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.

Levodopa-induced dyskinesia (LID) is an adverse effect that negatively impacts the quality of life of patients with Parkinson's disease (PD). Studies report that genetic variations in the genes of the pharmacogenetic pathway of the levodopa (L-DOPA) might be associated with LID development. The goal of the present study was to investigate a possible influence of functional genetic variants in the DRD1 (rs4532), DRD2 (rs1800497), DAT1 (rs28363170), and COMT (rs4680) genes with LID development. A total of 220 patients with idiopathic PD were enrolled. The genotyping for DRD1 (rs4532), DRD2 (rs1800497), DAT1 (rs28363170), and COMT (rs4680) polymorphisms were performed using Restriction Fragment Length Polymorphism (PCR-RFLP). Univariate and multivariate analyses were performed to assess the association of these polymorphisms and risk factors with LID development. Multivariate Cox regression analysis showed increased risk to LID development for both Levodopa Dose Equivalency (LED) (Hazard ratios (HR) = 1.001; 95% CI 1.00-1.01; p = 0.009) and individuals carrying the COMT L/L genotype (HR = 2.974; 95% CI 1.12-7.83; p = 0.010). Furthermore, when performed a Cox regression analysis adjusted for a total LED, we observed that the genotype COMT L/L had a 3.84-fold increased risk for LID development (HR = 3.841; 95% CI 1.29-11.37; p = 0.012). Our results suggest that before treating LID in PD patients, it is important to take into consideration genetic variant in the COMT gene, since COMT LL genotype may increase the risk for LID development.

Chronic pain and depression as factors associated with temporomandibular dysfunction in older adults with Parkinsons disease / Dor crônica e depressão como fatores associados à disfunção temporomandibular em pessoas idosas com doença de Parkinson

ABSTRACT Purpose: to investigate whether chronic pain and depression are factors associated with temporomandibular dysfunction (TMD) in older adults with Parkinson's disease. Methods: a cross-sectional study using the Research Diagnostic Criteria for Temporomandibular Disorders questionnaire. The clinical variables studied were chronic pain, depression, nonspecific physical symptoms including and excluding items of pain, and dentures use. The associations between the dependent and independent variables were evaluated by the chi-square odds ratio, with a 95% confidence interval. Results: a total of 81 older adults met the eligibility criteria - 67% were males, 74% were married or had a partner, 43% reported earning 1 to 2 minimum wages, and 47% were in the moderate stage of Parkinson's disease. TMD was identified in 22% of the sample, 12% reporting chronic pain. The statistical analysis showed an association between TMD and chronic pain (p = 0.001, OR = inf, 95% CI = 12.13 - inf) and between TMD and moderate-to-severe depression (p = 0.014, OR = 4.8, 95% CI = 1.14 - 23.51). Conclusion: it was verified that chronic pain and moderate-to-severe depression were the factors associated with TMD in older adults presented with Parkinson's disease.

RESUMO Objetivo: investigar se a dor crônica e a depressão representam fatores associados à disfunção temporomandibular (DTM) em idosos com doença de Parkinson. Métodos: estudo de corte transversal realizado no Hospital das Clínicas da Universidade Federal de Pernambuco, em 2018. Utilizou-se o questionário Critério de Diagnóstico de Pesquisa para Disfunções Temporomandibulares. As variáveis clínicas estudadas foram: dor crônica, depressão, sintomas físicos não específicos, incluindo e excluindo itens de dor e uso de prótese dentária. As associações entre as variáveis dependente e independentes foram avaliadas pelo teste do Odds Ratio do Qui-quadrado, com intervalo de confiança de 95%. Resultados: encontraram-se dentro dos critérios de elegibilidade 81 idosos, 67% eram do sexo masculino, 74% eram casados ou tinham companheiro, 43% declararam receber de 1-2 salários mínimos e 47% apresentavam-se no estágio moderado da doença de Parkinson. A DTM foi identificada em 22% da amostra e 12% dos participantes referiram presença de dor crônica. A análise estatística demonstrou associação entre DTM e dor crônica (p=0,001, OR=inf, IC95%=12,13-inf), bem como entre DTM e depressão moderada-severa (p=0,014, OR=4,8, IC95%=1,14 - 23,51). Conclusão: verificou-se que os fatores que estavam associados à DTM em idosos com doença de Parkinson foram dor crônica e depressão moderada-severa.

Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease.

Visual hallucinations are significant nonmotor symptoms in the course of treatment of Parkinson's disease. Previous studies have shown that the interindividual variability and pharmacogenetic profile of Parkinson's disease patients seem to influence the occurrence of visual hallucinations. In our study, we investigated a possible relationship of sequence variants in DRD1, DRD2, DRD3, DAT1, and COMT genes with the presence of visual hallucinations in Parkinson's disease patients. A total of 224 Brazilian patients from the Pro-Parkinson service at the Clinical Hospital of the University of Pernambuco, diagnosed with sporadic Parkinson's disease, were enrolled. Parkinson's disease patients were divided into 2 groups based on the presence or absence of visual hallucinations. The sequence variants for DRD1, DRD2, DRD3, DAT1, and COMT were determined through the polymerase chain reaction-restriction fragment length polymorphism technique. Multiple Poisson regression analyses showed that individuals carrying the DRD3 Ser/Ser and Ser/Gly genotypes presented increased prevalence ratios of visual hallucinations (9.7-fold and 4.4-fold, respectively; P < .001). Regarding DAT1 rs28363170, there was a 9.82-fold increase in the prevalence ratio in patients with the 10/11 genotype, 8.78-fold for the 10/8 genotype, and 2.44-fold for the 9/8 genotypes (P < .001, for all). In addition, visual hallucinations were also associated with use of transdermal patches with rotigotine (PR, 3.7; 95%CI, 1.2-10.9; P = .017) and rasagiline (PR, 2.8; 95%CI, 1.3-6.0; P = .006). Our results suggest that the genetic variants DRD3 and DAT1, along with other therapeutic confounders, may influence the prevalence ratio of visual hallucinations.

The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease.

OBJECTIVES: The aim of this study was to evaluate a possible relationship between DRD2/ANKK1 (rs1800497) and SLC6A3/DAT1 (rs28363170) gene polymorphisms with the response to levodopa (L-DOPA)-therapy in patients with Parkinson's disease (PD). METHODS: One hundred and ninety-five patients with idiopathic PD were investigated. Patients were genotyped for rs1800497 and rs28363170 polymorphisms using PCR-RFLP. Logistic regression was performed to assess the association of polymorphisms with the occurrence of the chronic complications of L-DOPA therapy. KEY FINDINGS: Our results showed association between the occurrence of dyskinesia with an increased greater disease severity (P = 0.007), higher L-DOPA dose (P = 0.007) and use of dopamine agonist (P = 0.020). Moreover, there were significant protective effects for age (P = 0.004) and male subjects (P = 0.006). CONCLUSIONS: Clinical and demographic characteristics of Brazilian PD patients and differences in DRD2 and DAT1 genes may to determine individual variations in the therapeutic response to L-DOPA in the Brazilian PD patients.

MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.

The most commonly used Parkinson's disease (PD) treatment is the replacement of dopamine by its levodopa precursor (l-dopa). Monoamine oxidase-B (MAO-B) and catechol-o-methyl transferase (COMT) are enzymes involved in the metabolism and regulation of dopamine availability. In our study we investigated the possible relation among selected single-nucleotide polymorphisms (SNPs) in the MAO-B (rs1799836) and COMT (rs4680) genes and the therapeutic response to levodopa (l-dopa). A total of 162 Brazilian patients from the Pro-Parkinson service of Clinics Hospital of Pernambuco diagnosed with sporadic PD and treated with levodopa were enrolled. PD patients were stratified into 2 groups according to the daily levodopa dose. MAO-B and COMT SNP genotyping was conducted by polymerase chain reaction-restriction fragment length polymorphism. After multivariate analysis, we observed a significant difference between PD groups for the following variables: sex (P = .02), longer duration of disease (P = .02), longer levodopa therapy duration (P = .01), younger onset of PD (P = .01), and use of COMT inhibitor (P = .02). We observed that patients carrying MAO-B (rs1799836) A and AA genotypes and COMT (rs4680) LL genotype suffered more frequently from levodopa-induced-dyskinesia. In addition, we found an increased risk of 2.84-fold for male individuals carrying the MAO-B G allele to be treated with higher doses of levodopa (P = .04). We concluded that before beginning PD pharmacological treatment, it is important to consider the genetic variants of the MAO-B and COMT genes and the sex, reinforcing the evidence that sexual dimorphism in the genes related to dopamine metabolism might affect PD treatment.

Individualized guidance and telephone monitoring in a self-supervised home-based physiotherapeutic program in Parkinson / Orientação individualizada e monitoramento telefônico em programa domiciliar fisioterapêutico autossupervisionado no Parkinson

Abstract Introduction: Home therapeutic exercises have been a target of interest in the treatment of the Parkinson's disease (PD). The way that the physical therapist guides and monitors these exercises can impact the success of therapy. Objective: To evaluate the effects of individualized orientation and monitoring by telephone in a self-supervised home therapeutic exercise program on signs and symptoms of PD and quality of life (QoL). Methods: Single-blind randomized clinical trials with 28 people with PD (Hoehn and Yahr 1 to 3). Patients were randomized into two groups: experimental and control. The experimental group had a meeting with individualized guidance about physiotherapy exercises present in a manual, received the manual to guide their activities at home and obtained subsequent weekly monitoring by telephone. The control group received the usual cares by the service. Both were orientated to carry out exercises three times a week during 12 weeks. Was evaluated: (1) activities of daily living (ADL) and motor examination sections of the Unified Parkinson's Disease Rating Scale (UPDRS) and QoL by the Parkinson Disease Questionnaire 39 (PDQ-39). The analysis between groups was performed by the Mann-Whitney test and intragroup through the Wilcoxon (p < 0.05). Results: Significant improvement in ADL (p= 0.001) and motor examination (p= 0.0008) of the UPDRS, PDQ-39 total (p = 0.027) and dimensions mobility (p = 0.027), emotional well-being (p= 0.021) and bodily discomfort (p = 0.027) in the experimental group compared to the control group. Conclusion: The individualized guidance and weekly monitoring by telephone in a self-supervised home therapeutic exercises program promoted positive effects on ADL, motor examination and QoL of people in early stages of PD.

Resumo Introdução: Exercícios terapêuticos domiciliares vêm sendo alvo de interesse no tratamento da doença de Parkinson (DP). A forma como o fisioterapeuta orienta e monitora estes exercícios pode impactar no sucesso da terapêutica. Objetivo: Avaliar os efeitos da orientação individualizada e do monitoramento por telefone em um programa de exercícios terapêuticos domiciliares autossupervisionados sobre os sinais e sintomas da DP e a qualidade de vida (QV). Métodos: Ensaio clínico randomizado simples-cego com 28 pessoas com DP (Hoehn e Yahr 1 a 3). Pacientes foram randomizados em dois grupos: experimental e controle. O grupo experimental teve um encontro com orientação individualizada sobre os exercícios de fisioterapia de um manual, recebeu o manual para orientar atividades em domicílio e obteve posterior monitoramento semanal por telefone. O grupo controle recebeu cuidados usuais do serviço. Ambos foram orientados a realizar exercícios três vezes por semana durante 12 semanas. Foram avaliadas: seções atividades da vida diária (AVD) e exame motor da Escala Unificada de Avaliação da Doença de Parkinson (UPDRS) e QV mediante Questionário de Doença de Parkinson 39 (PDQ-39). Foi realizada análise intergrupos (Mann-Whitney) e intragrupos (Wilcoxon) com p < 0.05. Resultados: Melhora significativa nas seções AVD (p = 0.001) e exame motor (p = 0.0008) da UPDRS, PDQ-39 total (p = 0.027) e dimensões mobilidade (p=0.027), bem-estar emocional (p = 0.021) e desconforto corporal (p=0.027) no grupo experimental quando comparado ao controle. Conclusão: A orientação individualizada e o monitoramento semanal por telefone em um programa de exercícios terapêuticos domiciliares autossupervisionados apresentaram efeitos positivos sobre AVD, exame motor e QV em estágios iniciais da DP.

Acupuncture as Adjuvant Therapy for Sleep Disorders in Parkinson's Disease.

There are few studies which attest the efficacy of acupuncture on treatment of sleep disturbs in Parkinson disease. The aimed of this randomized clinical trial was to evaluate the effects of acupuncture on sleep disturbs of 22 patients with diagnosis of idiopathic Parkinson disease (Hoehn-Yahr 1 to 3) who have assistance on the Pro-Parkinson Program of Clinical Hospital at Federal University of Pernambuco in Brazil. All participants were evaluated by Parkinson Disease Sleep Scale (PDSS) before and after 8 weeks. The experimental group was submitted to 8 sections (once a week) which had duration of 30 minutes. The control group had no intervention. The intervention was executed using the acupuncture points LR3 (Taichong), SP6 (Sanyinjiao), LI4 (Hegu), TE5 (Wai-Guan), HT7 (Shenmen), PC6 (Neiguan), LI11 (Quchi), GB20 (Fengchi). Paired analyses were obtained by Wilcoxon test and independent analyses were made according to Mann-Whitney test. This study presented a potential therapeutic benefit of acupuncture on sleep disturbs of Parkinson's disease patients. This study showed a possible therapeutic benefit through acupuncture in sleep disorders in patients with PD. However, we propose new studies related to the effects of acupuncture on the clinical symptoms and evolution of the disease.

Qualidade de vida de pessoas com doença de Parkinson após o tratamento com realidade virtual não imersiva / Quality of life of people with Parkinson's disease after treatment with non-immersive virtual reality

Objetivo: Analisar a influência do tratamento com jogos em realidade virtual não imersiva (RVNI) na qualidade de vida (QV) de pessoas com doença de Parkinson (DP). Métodos: Ensaio clínico não controlado, com 14 pessoas com DP entre os estágios I a IV da DP. O tratamento com RVNI ocorreu em 6 meses, com 1 avaliação inicial e 2 reavaliações trimestrais. Os instrumentos de medida de resultado foram o Questionário da Doença de Parkinson-39 (PDQ-39) e Questionário de Autopercepção de Desempenho. No protocolo de tratamento foi utilizado o Kinect® para Xbox 360 e os jogos Kinect Advenctures®, Your Shape Fitness Evolved® e Kinect Sports®. Na análise estatística do PDQ-39 foi aplicado o teste de Wilcoxon (p ≤ 0,05) e para o Questionário de Autopercepção de Desempenho foi empregada a análise qualitativa de conteúdo temático, com identificação de seis categorias. Resultados: Houve significância estatística após o período de 3 meses de tratamento com os jogos em RVNI, especificamente na mobilidade, bem estar emocional, estigma, cognição e pontuação total do PDQ-39. Depois de 6 meses de tratamento os resultados se mantiveram, não havendo novos ganhos. No entanto, por uma doença neurodegenerativa essa manutenção dos ganhos é favorável para o prognóstico funcional dos pacientes. Nas categorias temáticas, destacaram-se relatos de melhora na mobilidade, atividades de vida diária, bem estar emocional, estigma e desconforto corporal. Conclusão: O tratamento com RVNI beneficia a QV de pessoas com DP, principalmente quando abrange a mobilidade, bem estar emocional, estigma e cognição

Objective: To analyze the influence of treatment with non-immersive virtual reality games (VR) on the quality of life (QOL) of people with Parkinson's disease (PD). Methods: Uncontrolled clinical trial using 14 people with PD between stages I and IV of PD. Treatment with NIVR occurred for 6 months, 1 initial assessment and 2 quarterly re-evaluations. The instruments to measure the results were the Parkinson's Disease Questionnaire (PDQ-39) and a Self-Perception of Performance Questionnaire. The treatment protocol used was Kinect® for Xbox 360, and the following games: Kinect Advenctures®, Your Shape: Fitness Evolved®, and Kinect Sports®. Statistical analysis of the PDQ-39 used the Wilcoxon test (p ≤ 0.05) while the Self-Perception of Performance Questionnaire was analyzed qualitatively for thematic content, identifying six categories. Results: There was a statistically significant difference after 3 months of treatment with the NIVR games in terms of mobility, emotional well-being, stigma, cognition, and total score of the PDQ-39. After 6 months of treatment the results were maintained, but no further gains. However, for a neurodegenerative disease this maintenance of gains is favorable for the functional prognosis of the patients. In the thematic categories, what stood out was an improvement of reports on mobility, activities of daily living, emotional well-being, stigma, and bodily discomfort. Conclusion: Treatment with NIVR benefits QOL of people with PD, especially including mobility, emotional well-being, stigma, and cognition

Análise do risco de queda em pessoas com doença de Parkinson / Fall risk analysis in persons with Parkinson's disease

Introdução: Pessoas com Doença de Parkinson (DP) apresentam instabilidade postural com tendência a um aumento na frequência das quedas e fraturas em consequência do agravamento das alterações posturais. Objetivo: Analisar o risco de quedas em pessoas com Doença de Parkinson através da versão brasileira da Escala de Avaliação do Equilíbrio e da Marcha Orientada pelo Desempenho (POMA) e através do sistema de estabilidade Biodex. Material e métodos: Este foi um estudo transversal. O risco de quedas foi analisado nos sujeitos controles através da POMA. Nos sujeitos DP a análise foi feita com: escala de Hoehn e Yahr, POMA e com o sistema de estabilidade Biodex. Em ambos os grupos foram excluídos os indivíduos com doença vestibular, deficiência visual grave, labirintite ou outra que afetasse o equilíbrio. Resultados: A amostra foi composta por 58 sujeitos, sendo 31 com DP leve a moderada e 27 no grupo controle. O risco de queda avaliado através da POMA foi significativamente maior nos sujeitos com DP em relação ao controle (P < 0,0001). Conclusão: Neste estudo, o grupo com DP apresentou maior risco de queda do que a população sem a doença, com uma chance duas vezes maior de cair e risco de queda que aumentou com a progressão da doença. (AU)

Introduction: Persons with Parkinson's disease (PD) showing postural instability have increased frequency of falls and fractures as a result of the aggravation of postural changes. Objective: To evaluate the falls risk in persons with Parkinson's disease through Brazilian version of Performance Oriented Mobility Assessment (POMA) and Stability System Biodex. Methods: This was a cross-sectional study. The risk of falling was analyzed in controls subjects by POMA. In subjects PD the analysis was performed with original version Hoehn e Yahr (HY) scale; POMA and Stability System Biodex, falls risk protocol. Both groups excluded the subjects with vestibular disease, severe visual impairment, labyrinthitis or other that could affect the balance. Results: The sample consisted of 58 subjects, 31 with mild to moderate PD and 27 in the control group. The falls risk assessed by POMA was significantly higher in subjects with PD compared to control (P < 0.0001). Conclusion: In this study, the group with PD showed a higher risk of falling than people without the disease, with a twice as likely to fall and fall risk has increased with the progression of the disease. (AU)

Avaliação eletromiográfica da deglutição dos diferentes tipos clínicos da doença de Parkinson nas fases on e off / Electromyographic assessment of swallowing different types of clinical disease, Parkinson's on and off phases

OBJETIVO: avaliar os parâmetros eletromiográficos da deglutição dos diferentes tipos clínicos da doença de Parkinson idiopática nas fases on e off. MÉTODOS: foram estudados 20 pacientes com doença de Parkinson, divididos através da Escala Unificada de Avaliação da Doença de Parkinson em três grupos: tremulantes, rígido-acinético e misto. O exame de eletromiografia de superfície foi coletado sobre a musculatura supra-hióidea durante a deglutição de 3 ml e 10 ml de água e iogurte, que foi repetida 5 vezes para cada volume e consistência. Este protocolo foi realizado no antes e após a medicação, período off e on. RESULTADOS: verificou-se que na fase off, o grupo rígido-acinético apresentou as maiores médias de deglutições em partes e duração das eletromiografias de superfície, enquanto que o grupo misto apresentou as menores médias de amplitude. Na fase on, os três grupos tenderam a melhorar ou manter as médias das variáveis estudadas, porém não houve diferença significante entre os tipos clínicos, antes ou depois da Levodopa. CONCLUSÃO: a terapia medicamentosa através da Levodopa não apresenta diferenças consistentes nas eletromiografias de superfície da deglutição dos tipos clínicos da doença de Parkinson. .

PURPOSE: to evaluate the electromyographic parameters of swallowing different types of clinical of idiopathic Parkinson disease on and off phases. METHODS: the study was performed at the Clinic of Neurology, Hospital of the Federal University of Pernambuco. The population of the study were 20 patients with Parkinson disease, divided by Unified Scale for Assessment of Parkinson's disease in three groups: tremor, akinetic-rigid and mixed. The surface electromyography examination was collected on suprahyoid muscles during swallowing and 3 ml water and 10 ml of yoghurt, which was repeated 5 times for each volume and consistency. This protocol was carried out before and after the medication period off and on. RESULTS: it was found that the phase off, akinetic-rigid group had the highest average in parts of swallows and duration of surface electromyography, while the mixed group had the lowest average amplitude. In phase on the three groups tended to improve or maintain the averages of the variables, but there was no significant difference between the clinical types, before or after Levodopa. CONCLUSION: drug therapy through Levodopa shows no consistent differences in surface electromyography of swallowing the clinical types of Parkinson disease. .

The relationship between limit of Dysphagia and average volume per swallow in patients with Parkinson's disease.

The goal of this study was to obtain the limit of dysphagia and the average volume per swallow in patients with mild to moderate Parkinson's disease (PD) but without swallowing complaints and in normal subjects, and to investigate the relationship between them. We hypothesize there is a direct relationship between these two measurements. The study included 10 patients with idiopathic PD and 10 age-matched normal controls. Surface electromyography was recorded over the suprahyoid muscle group. The limit of dysphagia was obtained by offering increasing volumes of water until piecemeal deglutition occurred. The average volume per swallow was calculated by dividing the time taken by the number of swallows used to drink 100 ml of water. The PD group showed a significantly lower dysphagia limit and lower average volume per swallow. There was a significantly moderate direct correlation and association between the two measurements. About half of the PD patients had an abnormally low dysphagia limit and average volume per swallow, although none had spontaneously related swallowing problems. Both measurements may be used as a quick objective screening test for the early identification of swallowing alterations that may lead to dysphagia in PD patients, but the determination of the average volume per swallow is much quicker and simpler.

Quality of life related to swallowing in Parkinson's disease.

Swallowing difficulties in Parkinson's disease can result in decreased quality of life. The swallowing quality of life questionnaire (SWAL-QOL) is an instrument for specifically assessing quality of life with respect to swallowing, which has been little explored in patients with Parkinson's disease (PD). The goal of this study was to evaluate the quality of life with respect to swallowing in persons with PD compared to controls and at several stages of the disease using the SWAL-QOL. The experimental group was composed of 62 persons with PD at stages 1-4. Forty-one age-matched healthy subjects constituted the control group. The SWAL-QOL scores were significantly lower for the patients with PD than for the controls in all SWAL-QOL domains. Eating duration had the largest difference in score between persons with PD and the controls and the lowest mean score, followed by communication, fatigue, fear, sleep, and food selection. The scores of most domains were lower at later stages of the disease. The scores for eating duration, symptom frequency, and sleep were significantly lower at stage 4 than stages 1 and 2. In conclusion, patients with PD have significantly lower scores in all domains of the SWAL-QOL than normal controls. This means swallowing difficulties occurring in patients with PD negatively affect their QOL. Progression of the disease worsens swallowing QOL, more specifically in the domains of eating duration, symptom frequency, and sleep. This occurs mostly at later stages of the disease.

Pain characterization in patients with Parkinson's disease / Caracterização da dor em pacientes com doença de Parkinson

BACKGROUND AND OBJECTIVES: Pain in Parkinson's disease is a very frequent complaint and may precede the diagnoses of the disease. This study aimed at evaluating pain in a group of Parkinson's disease patients from a specialized treatment center. METHODS: This is a observational study of pain in Parkinson's disease patients from the Clinicas Hospital, Federal University of Pernambuco. The convenience sample, obtained between July and August 2011, was made up of 24 individuals, being 17 males and 7 females, aged between 42 and 50 (mean=64.3) years, and 48 and 66 (mean=58.7) years, respectively. Section III of the Unified Parkinson's Disease Rating Scale, Hoehn and Yahr (HY) scale according to the stage of the disease, McGill pain questionnaire and Mini Mental State Examination were used. RESULTS: Specific body region with most frequent pain was lumbar spine (50%). Categorized regions with highest complaint percentages were: trunk (66.7%) and limbs (37.5% upper; 37.5% lower). Most patients have referred pain in a single body region, regardless of analyzing specific or categorized regions (37.5%). There has been no significant difference in proportional scores obtained by each McGill questionnaire score component. Patients with rigid-akinetic Parkinson's disease had higher number of painful body regions. The comparison among McGill indices, according to predominant symptom and according to Parkinson's disease stage (HY) scores has not shown significant differences. CONCLUSION: In our study, all Parkinson's disease patients have referred pain. Although pain is one of the most frequent non-motor symptoms, many aspects regarding Parkinson's disease-related pain need further investigation, such as which would be the best pain categorization and which methodology could better distinguish different mechanisms of different types of pain. .

JUSTIFICATIVA E OBJETIVOS: A dor na doença de Parkinson é uma queixa muito frequente, podendo preceder o diagnóstico da doença. O objetivo deste estudo foi avaliar a dor num grupo de pacientes com doença de Parkinson de um serviço de atendimento especializado. MÉTODOS: Trata-se de um estudo observacional da dor em pacientes com doença de Parkinson no Hospital das Clínicas da Universidade Federal de Pernambuco. A amostra de conveniência, obtida entre julho e agosto de 2011, foi composta por 24 sujeitos, sendo 17 do gênero masculino e 7 do gênero feminino, com idades que variaram de 42 a 50 (média=64,3) anos e 48 a 66 (média=58,7) anos, respectivamente. Utilizou-se a sessão III da Escala Unificada de Avaliação da Doença de Parkinson, a classificação segundo o estágio da doença de Hoehn e Yahr (HY), o questionário de dor McGill e o Mini-Exame do Estado Mental. RESULTADOS: A região específica do corpo com dor mais frequente foi coluna lombar (50%). As regiões categorizadas com maior percentual de queixas foram: tronco (66,7%) e membros (37,5% - superiores; 37,5% - inferiores). A maioria dos pacientes referiu dor em apenas uma região do corpo, independentemente de se analisar as regiões específicas ou categorizadas (37,5%). Não houve diferença significativa na pontuação proporcional atingida por cada componente da pontuação do questionário McGill. Pacientes com doença de Parkinson do grupo rígido-acinético apresentaram maior número de regiões do corpo com dor. A comparação entre as pontuações dos índices de McGill, segundo o sintoma predominante e segundo o estágio da doença de Parkinson (HY) não apresentou diferença significativa. CONCLUSÃO: No presente estudo, todos os pacientes com ...

Verificação dos efeitos da Levodopa na deglutição de pacientes com doença de Parkinson / Verification of the effects of Levodopa on the swallowing of patients with Parkinson?s disease

Objetivo : Avaliar os efeitos da Levodopa na deglutição de pacientes com Doença de Parkinson (DP). Métodos : O estudo foi realizado no Programa Pró-Parkinson do Hospital das Clínicas da Universidade Federal de Pernambuco. Foram estudados 20 pacientes com DP idiopática e 12 sujeitos normais (grupo controle). A eletromiografia de superfície (EMGs) foi registrada sobre a musculatura supra-hióidea, durante a deglutição de 3 ml e 10 ml de água e iogurte. Cada volume foi repetido cinco vezes. Esse protocolo foi realizado no grupo com DP antes e após a medicação, período off e on, e no grupo controle, uma única vez. Resultados : A amplitude das EMGs foi significativamente maior nos sujeitos do grupo controle do que nos pacientes com DP (off), na deglutição de cada volume de água. A duração das EMGs foi significativamente maior na deglutição de 3 ml de água e iogurte em pacientes com DP (off). Durante a fase on, diferenças significativas não foram notadas. Conclusão : A administração de Levodopa em pacientes com DP parece influenciar a amplitude e duração da EMGs dos músculos supra-hióideos, aproximando as variáveis aos valores de normalidade. .

Purpose : To evaluate the effects of Levodopa on the swallowing of patients with Parkinson’s Disease (PD). Methods : The study was carried out in the Pro-Parkinson Program of the Hospital das Clinicas of the Federal University of Pernambuco. Twenty patients with idiopathic PD and 12 normal subjects (control group) were studied. The surface Electromyography (sEMG) was recorded over the suprahyoid musculature during swallowing of 3 ml and 10 ml of water and yogurt. Each volume was repeated five times. This protocol was carried out on the group with PD before and after the medication, off and on periods, and on the control group, a single time. Results : The amplitude of the sEMG was significantly greater for subjects of the control group than for the patients with PD (off), regarding swallowing of each volume of water. The duration of the sEMG was significantly greater for the swallowing of 3 ml of water and yogurt in patients with PD (off). During the on phase, no significant differences were noted. Conclusion : The administration of Levodopa on patients with PD seems to influence the amplitude and duration of the sEMG of suprahyoid muscles, approximating the variables to the values of normalcy. .

Monitorando a deglutição através da eletromiografia de superfície / Monitoring swallowing with surface electromyography

OBJETIVO: descrever o método de registro da eletromiografia de superfície através da utilização de um protocolo desenvolvido para o estudo da deglutição e demonstrar a deglutição de um paciente com doença de Parkinson e de um sujeito normal através do registro da eletromiografia de superfície (EMGs). MÉTODOS: para ilustrar os parâmetros eletrofisiológicos registrados após execução do protocolo foram utilizados dois voluntários do sexo feminino, sendo um sem doença e outro apresentando doença de Parkinson (DP) no estágio III de acordo com a escala de Hoehn e Yahr. Os parâmetros analisados pelo foram: a duração da atividade elétrica durante a deglutição, a amplitude (rms) e o limite de disfagia. RESULTADOS: os resultados mostram diferenças entre os eletromiogramas ilustrativos. CONCLUSÃO: a EMGs pode ser utilizada como método de avaliação e monitorização da deglutição de sujeitos sem doença e com DP.

PURPOSE: to describe the registering method of the surface electromyography (sEMG) through the use of a protocol developed for swallowing study and to demonstrate the swallowing pattern of a patient with Parkinson’s disease and of normal individuals through the sEMG registering. METHODS: to illustrate the registered electrophysiologic parameters execution of the protocol we used two volunteers of the feminine gender, being one without disease and the other one with Parkinson’s disease (PD) in III period of training in accordance with the scale of Hoehn and Yahr. The analyzed parameters had been the duration of the electric activity during swallowing, the amplitude (rms) and the dysphagia limit. RESULTS: the results show differences amongst the illustrative electromyograms. CONCLUSION: sEMG can be used as method for evaluating and monitoring the swallowing pattern of citizens with no disease and with PD.